
Figure 1


PE-conjugated
ACE2
SARS-CoV-2
RBD
SARS-CoV RBD
RaTG13 RBD
MagPlex Avidin-Microsphere
PE-conjugated
ACE2
Neutralizing
antibody
Binding
antibody



ACE2 binding
Net MFI
10000
8000
6000
4000
2000
0
0.1
1
10
100
1000
10000
Concentration (ng/ml)
SARS-CoV-2
SARS-CoV-2 B.1.1.7
SARS-CoV-2 B.1.351
SC2r-CoV GX-P5L
SC2r-CoV RaTG13
SARS-CoV

Figure 2



A
% inhibition
100
80
60
40
20
0
-20
SARS-CoV-2
SARS-CoV-2 B.1.1.7
SARS-CoV-2 B.1.351
SC2r-CoV RaTG13
SC2r-CoV GX-P5L
SARS-CoV
B
% Inhibition
C
% Inhibition
D
% inhibition

Figure 3





Log NT50 Titer
5
4
3
2
1
0
-1
SARS-COV-2
SARS-CoV-2 B.1.1.7
SARS-CoV-2 B.1.351
SC2r-CoV RaTG13
SC2r-CoV GX-P5L
SARS-CoV
SARS-Vaccinated
Healthy-Vaccinated
COVID-19 Patient
SARS Patient

Figure 4



100
80
60
40
20
0
-20
% Inhibition
200
400
600
800
1000
Concentration (ng/ml)
SARS-CoV-2
SARS-CoV-2 B.1.1.7
SARS-CoV-2 B.1.351
SC2r-CoV RaTG13
SC2r-CoV GX-P5L
SARS-CoV

A


100
80
60
40
20
0
-20
% Inhibition
SARS-CoV-2
SARS-CoV-2 B.1.1.7
SARS-CoV-2 B.1.351
SC2r-CoV RaTG13
SC2r-CoV GX-P5L
SARS-CoV
SARS-Vaccinated
Healthy-Vaccinated
COVID-19 patient
SARS patient

B

Figure 5


Log NT50 Titer
5
4
3
2
1
0
SARS-COV-2
B.1.1.7
B.1.351
RaTG13
GX-P5L
SARS-CoV
SARS-CoV-2
RaTG13
GX-P5L
RmYN02
SARS-CoV
HKU1